Fulgent Genetics Inc (FLGT) Stock AnalysisFLGTFulgent Genetics Inc

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Fulgent Genetics Inc is not a good buy right now due to its current price of $19.81, which is close to the analyst price target of $19. The stock has a low RSI of 29.426, indicating oversold conditions, but the recent performance shows a significant decline of 22.59% year-to-date. Furthermore, hedge funds are selling, with a 169.46% increase in selling activity over the last quarter, suggesting a lack of confidence in the stock's near-term prospects.

3 analysts cover FLGT: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 32.50.